awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q55291267-02951FA9-4F2C-4625-BEA4-39A05585F9C8
Q55291267-02951FA9-4F2C-4625-BEA4-39A05585F9C8
BestRank
Statement
http://www.wikidata.org/entity/statement/Q55291267-02951FA9-4F2C-4625-BEA4-39A05585F9C8
Exploring Landscape of Drug-Target-Pathway-Side Effect Associations.
P2860
Q55291267-02951FA9-4F2C-4625-BEA4-39A05585F9C8
BestRank
Statement
http://www.wikidata.org/entity/statement/Q55291267-02951FA9-4F2C-4625-BEA4-39A05585F9C8
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
4ec9caa98eddac60b8d8da1055108a7a8a6edc60
P2860
A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer.